Wolfe Research initiated coverage of uniQure (QURE) with a Peer Perform rating and no price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe wants more clarity on uniQure’s lead program AMT-130 before recommending the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure: Strengthening Gene Therapy Platform and Fabry Data Undervalued, Supporting Buy Rating and $70 Target
- Balanced Risk/Reward at uniQure: Early Promise for AMT-191 Offset by Regulatory and Competitive Uncertainty Around AMT-130
- uniQure announces preliminary AMT-191 Phase I/IIa data
- uniQure initiated with an Equal Weight at Barclays
- uniQure updates gene therapy pipeline and regulatory outlook